CDC report shows decrease in US tobacco product use

Mar.23.2022
CDC report shows decrease in US tobacco product use
CDC's survey showed a decrease in overall tobacco product usage among American adults, but 19% still use some form of tobacco.

According to foreign media on March 17, 2022, report that...

 

The Centers for Disease Control and Prevention (CDC) released the findings of their weekly report on incidence and mortality rates today, revealing an overall decrease in the use of commercial tobacco products, combustible tobacco products, cigarettes, e-cigarettes, and two or more tobacco products among U.S. adults from 2019 to 2020. However, as of 2020, nearly one-fifth of adults (estimated 47.1 million) reported current (daily or some days) tobacco product use, including 30.8 million smokers.

 

In order to assess recent estimates of tobacco product use among adult Americans aged 18 and over, the Center for Disease Control and Prevention (CDC) analyzed data from the 2020 National Health Interview Survey. The survey evaluated the use of five tobacco products: cigarettes, cigars (cigars, small cigars, or filtered little cigars), pipes (regular pipes, water pipes, or hookahs), electronic cigarettes, and smokeless tobacco.

 

A recent study has found that by 2020, 19.0% of American adults will have used at least one tobacco product, which is slightly lower than the 20.8% reported in 2019. Despite this decrease, cigarettes remain the most commonly used product at 12.5%, followed by e-cigarettes at 3.7%, cigars at 3.5%, smokeless tobacco at 2.3%, and pipes at 1.1%.

 

We have made significant progress in preventing and reducing tobacco use in this country through the use of validated strategies and implementation of effective policies," said Dr. Karen Hacker, director of the CDC's National Center for Chronic Disease Prevention and Health Promotion. "Although adult tobacco use has dramatically decreased, our work is far from over. We must continue to address tobacco-related health disparities and inequities to ensure that everyone has the opportunity to be as healthy as possible.

 

Despite a decrease, the usage of combustible products remains high.

 

A new study reveals that smoking rates among adults have dropped to their lowest point since 1965, when it was 42%. While the percentage of adults who smoke has decreased from 14.0% in 2019 to 12.5% in 2020, nearly 31 million American adults still reported smoking in 2020. Among adults who currently use tobacco products, over three-quarters use combustible products like cigarettes, cigars, and pipes, which are the leading cause of tobacco-related illness, disability, and death in the United States.

 

In the United States, between 2019 and 2020, there was a decrease in the percentage of adults using other tobacco products, including e-cigarettes, which went from 4.5% to 3.7%. The use of combustible tobacco products also decreased from 16.7% to 15.2%. Additionally, the percentage of people using two or more tobacco products also decreased from 3.9% to 3.3%.

 

Factors that may contribute to a decline in smoking and tobacco use include influential anti-tobacco media campaigns such as the CDC's "Tips From Former Smokers," smoke-free policies, and policies that restrict the supply of specific types of tobacco products, such as flavored products.

 

Differences in the use of tobacco products

 

By 2020, significant differences still exist in the use of tobacco products among various adult population groups in the United States. These groups include:

 

Men (5%).

 

Nine percent of adults aged 25 to 44 years old.

 

34.9% of adult non-Hispanic American Indian/Alaska Native individuals and 1% of adult non-Hispanic individuals are classified as belonging to other races.

 

Three percent of adults live in rural (non-urban) areas.

 

The highest level of education attained by adults is a General Educational Development (GED) certificate, which accounts for 40.5%.

 

25.2% of adults have a household annual income less than $35,000.

 

Adults who identify as lesbian, gay, or bisexual (1%).

 

27.3% of adults do not have health insurance, while 6% rely on Medicaid or other forms of subsidized health insurance.

 

Four percent of adults have disabilities.

 

Nearly 30% of adults experience anxiety and 6% experience depression on a regular basis.

 

(Source: Center for Disease Control)

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Indonesian Parliament Reviews Narcotics Law Draft, May Include Vape Ban Proposal
Indonesian Parliament Reviews Narcotics Law Draft, May Include Vape Ban Proposal
According to Beritasatu, Commission III of the Indonesian House of Representatives is reviewing the Draft Law on Narcotics and Psychotropics and considering including a proposal from the National Narcotics Agency (BNN) to ban vapes.
Apr.10 by 2FIRSTS.ai
Swedish Politicians Ask European Commission to Clarify Legality of France’s Nicotine Pouch Ban
Swedish Politicians Ask European Commission to Clarify Legality of France’s Nicotine Pouch Ban
France’s ban on oral nicotine pouches has triggered an immediate response in Sweden. Swedish Minister for Foreign Trade Benjamin Dousa said Sweden had mobilized strongly against the ban and argued that it constitutes a clear obstacle to the free movement of goods within the EU single market. Swedish officials say the measure affects a strategically important domestic industry and conflicts with Sweden’s harm-reduction approach to public health.
Apr.14 by 2FIRSTS.ai
Russian Lawmaker Says Vape Circulation Licensing Will Be Regulated by Law in the Coming Months
Russian Lawmaker Says Vape Circulation Licensing Will Be Regulated by Law in the Coming Months
Alexander Tolmachev, deputy chairman of the Russian State Duma Committee on Youth Policy, said the issue of licensing vape circulation will be resolved at the legislative level in the coming months. He said a significant share of such products currently on the market are counterfeit, that their real nicotine concentration may be several times higher than stated, and that the composition of the liquid is unknown.
Mar.18 by 2FIRSTS.ai
PMJ Expands SENTIA Tobacco Stick Lineup, Adds Blueberry Menthol Capsule Flavor
PMJ Expands SENTIA Tobacco Stick Lineup, Adds Blueberry Menthol Capsule Flavor
Philip Morris Japan (PMJ) announced that it will launch “SENTIA Purple Capsule,” the first capsule-equipped product in its SENTIA lineup dedicated to the heated tobacco “IQOS ILUMA” series, as an early release in Japan. The product will roll out nationwide starting from IQOS Stores, and will enter tobacco retail channels nationwide from April 6.
Mar.03 by 2FIRSTS.ai
Product | OXVA launches SlimStick X in Europe and the U.S., shifting from pre-filled to open-system refilling
Product | OXVA launches SlimStick X in Europe and the U.S., shifting from pre-filled to open-system refilling
OXVA has recently launched its new e-cigarette, the SlimStick X. Unlike its predecessor, the SlimStick, which used a pre-filled pod system, the SlimStick X adopts an open-system refillable design, featuring a 2ml pod, a 1.0Ω coil, and a 1400mAh battery. The product has entered online retail channels in markets including the United States, the United Kingdom, Greece, and Spain, with a price of about $23.99.
Mar.06 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24